Rep. Matt Gaetz, Trump Ally, Sponsors Medical Pot Bill
*By Jacqueline Corba*
Freshman Congressman Matt Gaetz (R-FL) is on a mission to pass a bill that would allow for expanded medical marijuana research.
"Research can demystify who is right and who is wrong," Gaetz told Cheddar's CannaBiz Tuesday. "It's kind of nice to let the science guide our policy making."
Last week, the [Medical Marijuana Act](https://gaetz.house.gov/media/press-releases/congressman-matt-gaetz-applauds-passage-medical-cannabis-bill-through-house) sponsored by Gaetz passed the U.S. House Judicial Committee with bipartisan support.
It's a "landmark moment" Gaetz said; it's the first time Republicans in control of Congress have passed a medical marijuana bill through committee. Next it will head to the House floor for a vote.
"I'm super excited about what potential cannabis has in healthcare, and I think we'll learn a lot more if we're not so stupid as a government to make the research illegal," Gaetz said.
The act would give research institutions "safe harbor" to study the potential uses, benefits, and risks of the drug, which remains a Schedule I classification under the federal law alongside heroin and LSD.
"I think that marijuana policy has in many ways been victimized by the overall chilled relationship between the White House and the Department of Justice," Gaetz said.
"I think it is really Jeff Sessions who opposes medical marijuana, and I'm not entirely sure he and President Trump will be on one another's Christmas lists going forward."
For Gaetz, Washington is obstructing its own view.
"Washington just needs to get out of the way so that we can really see the potential."
For full interview [click here](https://cheddar.com/videos/medical-cannabis-research-act-passes-first-hurdle-in-congress).
David Stryzewski, CEO of Sound Planning Group, joins Cheddar News' Closing Bell, where he says that some of the major stock positions are getting the most lift to the upside as the major indexes climb higher to begin the week.
Markets opened slightly higher to kick off the final trading week of the year as investors continue to watch the Omicron variant in the U.S. Sean O'Hara, President, Pacer ETFs joined Cheddar's Opening Bell to discuss what drove early market activity.
Carlo and Baker kick off the weirdest week of the year with all the news you missed over the holiday weekend, including calls for the CDC to shorten its isolation window as Omicron sweeps through the country.
Former professional tennis player Patrick McEnroe joined Cheddar to discuss the troubling issues surrounding player Peng Shuai who appeared potentially to have been silenced following her social media post accusing former Vice-Premier Zhang Gaoli of sexual assault. Shuai's subsequent disappearance, reappearance, and apparent retraction of the accusation in an interview only added to worries. "When this happened, all of us in the tennis community were very concerned. And, by the way, another thing Peng said in this interview was that she doesn't speak very good English," McEnroe noted. "Well I can assure you, she speaks darn good English, 'cause I spoke to her on many occasions over the last 15 years."
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
The S&P closed at a record at the major markets ended Thursday's session higher for a third straight day. Adam Coons, Portfolio Manager at Winthrop Capital Management, joins Cheddar News' Closing Bell, where he discusses what has investors feeling jolly before Christmas, and gifts investors with winning buying opportunities entering 2022.
The Supreme Court will hear arguments on President Joe Biden's vaccine mandates for large companies and health care workers on January 7, 2022. The mandates will remain in place until then.
